← Leaderboards
Chandrajit Premanand Raut
Brigham And Women'S Hospital
$1,499,012
Attributed
$4,497,037
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $749.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,497,037 · 2
By mechanism
R01$4,497,037 · 2
Top collaborators
- Yolonda L Colson8 shared
- Mark W Grinstaff8 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Gregory L Stahl$14,189,628
- Simon C Body$5,470,378
- Charles David Collard$158,517
- David Bradley Lautz$638,315
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroIntraperitoneal TherapyFlexibilityInvadedImplantationIncidenceDrug Delivery SystemsDoseFilmFailureHealingImplantAnimalsBedsAdjuvant TherapyChemotherapyAbdomenDistantAnatomyCell Cycle KineticsCell DeathExcisionAnimal ModelIn Vivo
Grant awards (8)
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$712,043
R01 · FY2025 · CA · contact PI
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$676,443
R01 · FY2024 · CA · contact PI
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$695,566
R01 · FY2023 · CA · contact PI
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$749,261
R01 · FY2022 · CA · contact PI
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$404,583
R01 · FY2019 · EB
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$421,129
R01 · FY2018 · EB
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$407,644
R01 · FY2017 · EB
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$430,368
R01 · FY2016 · EB